P
Peter H. Schafer
Researcher at Celgene
Publications - 208
Citations - 10746
Peter H. Schafer is an academic researcher from Celgene. The author has contributed to research in topics: Lenalidomide & Apremilast. The author has an hindex of 52, co-authored 204 publications receiving 9683 citations.
Papers
More filters
Journal ArticleDOI
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
Christine Galustian,Brendan Meyer,Marie-Christine Labarthe,Keith Dredge,Deborah C. Klaschka,Jake Y. Henry,Stephen Todryk,Roger Shen-Chu Chen,George W. Muller,David I. Stirling,Peter H. Schafer,J. Blake Bartlett,Angus G. Dalgleish +12 more
TL;DR: The data provide one explanation for adjuvant properties of lenalidomid and pomalidomide and suggest that they may help overcome an important barrier to tumour-specific immunity in cancer patients.
Journal ArticleDOI
Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.
Peter H. Schafer,Anastasia Parton,Anita Gandhi,Lori Capone,Mary Adams,Lei Wu,Justin B. Bartlett,Loveland Ma,Amos Gilhar,Cheung Yf,George S. Baillie,Houslay,Man Hw,G. W. Muller,D. I. Stirling +14 more
TL;DR: The inhibitory effects of apremilast on pro‐inflammatory responses of human primary peripheral blood mononuclear cells, polymorphonuclear Cells, natural killer cells and epidermal keratinocytes were explored in vitro, and in a preclinical model of psoriasis.
Journal ArticleDOI
Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.
TL;DR: Apremilast is an orally available targeted PDE4 inhibitor that modulates a wide array of inflammatory mediators involved in psoriasis and psoriatic arthritis, including decreases in the expression of inducible nitric oxide synthase, TNF-α, and interleukin (IL)-23 and increases IL-10.
Journal ArticleDOI
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro.
Keith Dredge,Rebecca Horsfall,Simon P. Robinson,Ling-Hua Zhang,Ling Lu,Yang Tang,Michael A. Shirley,George W. Muller,Peter H. Schafer,David I. Stirling,Angus G. Dalgleish,J. Blake Bartlett,J. Blake Bartlett +12 more
TL;DR: Oral administration of lenalidomide attenuates growth factor-induced angiogenesis in vivo and significantly inhibits vascularization in a dose-dependent manner, suggesting a potential mechanism of action for its anti-migratory and subsequent anti-angiogenic effects.
Journal ArticleDOI
Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.
Peter H. Schafer,Anastasia Parton,Lori Capone,Dorota Cedzik,Helen Brady,Jilly F. Evans,Man Hw,G.W. Muller,D.I. Stirling,Rajesh Chopra +9 more
TL;DR: The pharmacological effects of apremilast are consistent with those of a targeted PDE4 inhibitor, with selective effects on innate immune responses and a wide therapeutic index compared to its gastrointestinal side effects.